Last reviewed · How we verify
Bupivacaine 0.167%
Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Local and regional anesthesia for surgical and diagnostic procedures, Pain management in infiltration anesthesia, nerve blocks, and epidural/spinal anesthesia.
At a glance
| Generic name | Bupivacaine 0.167% |
|---|---|
| Also known as | Marcaine |
| Sponsor | Bozyaka Training and Research Hospital |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine reversibly binds to and inactivates voltage-gated sodium channels on the inner surface of nerve cell membranes, thereby preventing depolarization and action potential propagation. This results in a loss of sensation in the area where it is administered. The drug has a relatively long duration of action compared to other local anesthetics due to its high lipophilicity and protein binding.
Approved indications
- Local and regional anesthesia for surgical and diagnostic procedures
- Pain management in infiltration anesthesia, nerve blocks, and epidural/spinal anesthesia
Common side effects
- Systemic toxicity (CNS effects: tremor, seizures, loss of consciousness)
- Cardiovascular effects (hypotension, bradycardia, arrhythmias)
- Local reactions (pain, erythema at injection site)
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine 0.167% CI brief — competitive landscape report
- Bupivacaine 0.167% updates RSS · CI watch RSS
- Bozyaka Training and Research Hospital portfolio CI